Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
Anthony V. Serritella, Amy K. Taylor, Michael Haffner, Wassim Abida, Alan H. Bryce, Lawrence I. Karsh, Scott T. Tagawa, Przemyslaw Twardowski, Andrew J. Armstrong, Joshua M. Lang
Abstract
BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. RESULTS/CONCLUSIONS: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.